Overview

Eribulin and Lenvatinib in Advanced Solid Tumors

Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia G. Kaklamani
Collaborator:
Eisai Inc.
Treatments:
Lenvatinib